Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.1823
- Book/Share 15.7357
- PB 7.3871
- Debt/Equity 1.2679
- CurrentRatio 1.3154
- ROIC 0.149
- MktCap 144851799374.0
- FreeCF/Share 7.5253
- PFCF 15.4608
- PE 23.0298
- Debt/Assets 0.4477
- DivYield 0.0269
- ROE 0.3294
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
News
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
Published: October 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Dividend Shields: Top 5 Income Stocks
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cut expectations, resulting in a slight market pullback, though 89% of traders still predict an October rate reduction. Beyond shifting rate cut expectations, seasonal weakness, upcoming earnings, and concerns around stretched valuations could contribute to market volatility.
Read More
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
Read More
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Baird Global Healthcare Conference 2025 September 10, 2025 11:25 AM EDT Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Participants Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Presentation Brian Skorney Senior Research Analyst Good afternoon, everyone.
Read More
Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Well, thanks, everyone, for joining us.
Read More
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Published: September 04, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund.
Read More
US plans to bring Gilead HIV drug to market in high-burden HIV countries
Published: September 04, 2025 by: Reuters
Sentiment: Positive
The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over three years.
Read More
Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Awesome. Thank you very much for joining us today.
Read More
Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Dietmar Berger - Chief Medical Officer Conference Call Participants Carter Gould - Cantor Fitzgerald & Co., Research Division Presentation Carter Gould Research Analyst Okay. Good morning, and welcome to the Cantor Global Healthcare Conference.
Read More
Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales
Published: September 02, 2025 by: Seeking Alpha
Sentiment: Positive
Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves competitors in the HIV-1 therapeutics market far behind, demonstrating record sales figures. In addition, the launch of Livdelzi and lenacapavir was extremely successful, which offsets the weak performance of its CAR T-cell therapies.
Read More
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
Published: August 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
Read More
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Read More
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Read More
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
Read More
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Read More
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Final Trades: Gilead, Blackstone, Disney and Visa
Published: July 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Calls of the Day: Gilead, Chipotle and P&G
Published: July 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading Player
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment. Explore the HIV market with our comprehensive report, analyzing disease overview, epidemiology, and current treatments. Discover unmet needs, R&D strategies, and market trends from 2023-2033 in the 7 major markets (US, France, Germany, Italy, Spain, UK, Japan). Optimize your strategic approach with pipeline insights and competitive assessment.
Read More
Why Merck Is A Better Dividend Stock Than Gilead Sciences
Published: July 16, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer dividend growth streak, a higher recent dividend increase, and a superior PEGY ratio. Both companies have similar payout ratios and mixed buyback histories, but GILD's inventory management is notably better than MRK's.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600